Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
暂无分享,去创建一个
Gord Glendon | Lesley McGuffog | Daniel Barrowdale | Sue Healey | Rosalind Eeles | Cindy Goh | Ignacio Blanco | Honglin Song | Ava Kwong | Linda Steele | Irene L Andrulis | Georgia Chenevix-Trench | Amanda E Toland | Stephen J Chanock | Diether Lambrechts | Paul D P Pharoah | Ellen L Goode | Brooke L Fridley | Montserrat Garcia-Closas | Andrew K Godwin | Susan Peock | Douglas F Easton | Douglas A Levine | Mitchell H Gail | Åke Borg | Alice S Whittemore | Robert L Nussbaum | Weiva Sieh | Marco Montagna | Beth Y Karlan | D Gareth Evans | Ulf Kristoffersson | Javier Benítez | Galit Hirsh-Yechezkel | Siegal Sadetzki | Olga Sinilnikova | Conxi Lázaro | Valerie McGuire | Charlie Gourley | Debra Frost | Mark H Greene | A. Whittemore | R. Nussbaum | S. Chanock | M. García-Closas | B. Fridley | E. Goode | P. Hartge | B. Karlan | J. Benítez | M. Gail | R. Eeles | D. Easton | P. Pharoah | D. Lambrechts | M. Greene | A. Antoniou | Å. Borg | D. Levine | H. Olsson | M. Gore | D. Evans | G. Chenevix-Trench | C. Lázaro | I. Andrulis | G. Glendon | A. Toland | J. Tyrer | S. Neuhausen | S. Gayther | L. McGuffog | A. Godwin | J. Gross | A. Chetrit | S. Peock | D. Frost | O. Sinilnikova | K. Moysich | M. Daly | C. Gourley | M. Beattie | L. Senter | V. McGuire | C. Michie | W. Sieh | C. Walsh | Honglin Song | A. Jensen | S. Kjær | E. Høgdall | D. Barrowdale | S. Healey | I. Blanco | M. Montagna | S. Ramus | A. Kwong | L. Steele | P. Mai | J. Loud | Salina B. Chan | I. Cass | E. Ma | E. Despierre | K. Bolton | S. Johnatty | M. J. García | S. Sadetzki | Patricia Hartge | Flora Lubin | Antonis C Antoniou | O. Gordon | Susan J Ramus | Simon A Gayther | Jonathan Tyrer | Estrid Høgdall | Kirsten B Moysich | Susanne Krüger Kjær | María J García | Mary B Daly | Susan Neuhausen | Jennifer T Loud | Phuong L Mai | Evelyn Despierre | Allan Jensen | Leigha Senter | G. Hirsh-Yechezkel | E. D'andrea | Håkan Olsson | S. K. Kjaer | Christine Walsh | Hampus Olsson | Mary S Beattie | Angela Chetrit | Jenny Gross | Sharon E Johnatty | Martin E Gore | U. Kristoffersson | Emma D'Andrea | Edmond S K Ma | Kelly L Bolton | Andrew J Li | Maria Ornella Nicoletto | Caroline O Michie | Salina Chan | Ilana Cass | Ronald Leuchter | Ora Gordon | F. Lubin | M. O. Nicoletto | A. Li | M. Gore | R. Leuchter | Å. Borg | D. Evans | V. Mcguire | Paul D. P. Pharoah | C. Goh | M. García | M. Nicoletto
[1] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[2] Olga Anczuków,et al. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon , 2006, Human mutation.
[3] W. Foulkes. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis , 2005, Familial Cancer.
[4] D. Easton,et al. Variation in BRCA1 cancer risks by mutation position. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[5] D. Stoppa-Lyonnet,et al. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. , 2002, Human molecular genetics.
[6] Jan Lubinski,et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Whittemore,et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis , 2008, British Journal of Cancer.
[8] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[9] J. Lubiński,et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Boshuizen,et al. Multiple imputation of missing blood pressure covariates in survival analysis. , 1999, Statistics in medicine.
[11] Theo Stijnen,et al. Using the outcome for imputation of missing predictor values was preferred. , 2006, Journal of clinical epidemiology.
[12] Barry Rosen,et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.
[13] R. L. Baldwin,et al. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. , 2006, Gynecologic oncology.
[14] J. Boyd,et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.
[15] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[16] B. Ponder,et al. Survival in Familial, BRCA1 -associated, and BRCA2- associated Epithelial Ovarian Cancer 1 , 1999 .
[17] R. Eeles,et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[19] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Graham,et al. How Many Imputations are Really Needed? Some Practical Clarifications of Multiple Imputation Theory , 2007, Prevention Science.
[21] E. Friedman,et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Hess,et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.
[23] R. L. Baldwin,et al. Improved survival in women with BRCA‐associated ovarian carcinoma , 2003, Cancer.
[24] S. Seal,et al. Brave new now , 2013, Nature Genetics.
[25] J. Klijn,et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.
[26] I. Jacobs,et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark , 2008, Clinical Cancer Research.
[27] D. Fishman,et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.
[28] Csilla Szabo,et al. The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.
[29] B. Ponder,et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Cancer research.
[30] J. Krischer,et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.
[31] D. Easton,et al. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.
[32] D. Livingston,et al. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.
[33] Georgia Chenevix-Trench,et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.
[34] P. Spellman,et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.
[35] L. Cope,et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.
[36] R. Buller,et al. Failure of BRCA1 dysfunction to alter ovarian cancer survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] R. Brookmeyer. Biased Sampling of Cohorts , 2005 .
[38] G. Mills,et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Dieter Niederacher,et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.
[40] M. Stratton,et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.
[41] F. Couch,et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.
[42] G M Lenoir,et al. A BRCA1 nonsense mutation causes exon skipping. , 1998, American journal of human genetics.